Abstract: . . .  Cancer Society grantees are: • Anti-angiogenesis drugs that block the supply of new blood vessels to breast tumors • How differences in the ability to metabolize alcohol influence breast cancer risk • How a woman’s genetic makeup determines her response to treatment • New molecular targets for anticancer dr . . .
. . .  Review Group, a collaboration formed by the National Cancer Institute of prominent members of the scientific, medical, advocacy, and industry communities, released their rec- ommendations for a national breast cancer research agenda. 45 The report included research goals in biology, etiology, genetics, prevention, detection and diagnosis, treatment, control, and outcomes. Among the goals in these eight areas are: • to expand knowledge of normal breast development and the earliest breast lesions. • to identify modifiable risk factors and to investigate the interaction between genes and environment. . . .
. . .  modifiable risk factors and to investigate the interaction between genes and environment. • to identify genetic mutations that occur at each stage of breast cancer development and progression, and evaluate these changes as targets for intervention. • to identify surrogate endpoint biomarkers to serve as early indicators of intervention effectiveness. • to develop better breast imaging and other technologies for diagnosis of clinically significant disease and better prediction of clinical outcomes. • to encourage development of innovative treatments in academic settings, and to test their effectiveness . . .
. . .  collaboration formed by the National Cancer Institute of prominent members of the scientific, medical, advocacy, and industry communities, released their rec- ommendations for a national breast cancer research agenda. 45 The report included research goals in biology, etiology, genetics, prevention, detection and diagnosis, treatment, control, and outcomes. Among the goals in these eight areas are: • to expand knowledge of normal breast development and the earliest breast lesions. • to identify modifiable risk factors and to investigate the interaction between genes and environment. • to identify . . .
. . .  mechanisms underlying behavioral change, and identify how psychosocial factors influence disease response and survival. • to better understand the effects of multimodal treatments, and improve methods to study patient-focused outcomes across the continuum of age and race/ethnicity. Page 17 Breast Cancer Facts & Figures 15 researchers to design rational therapeutics that may have greater efficacy and fewer side effects than con- ventional chemotherapy. Forty to 50 anti-angiogenesis compounds, drugs that starve the tumor of the blood it needs in order to grow, are in development for breast cancer . 46 . . .
--3000,5,300,3078,51450